EN DE
STOCK COMPARISON

Jw Cayman Therapeutics Co vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Jw Cayman Therapeutics Co (2126) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 5, 2026.

As of Aug 5, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Jw Cayman Therapeutics Co trades at HK$1.61 versus a fair value of HK$0.17 (-89%), while Vertex Pharmaceuticals trades at $477 versus $279 (-42%).
Jw Cayman Therapeutics Co
2126.HK · HKD · Health Care
-89%
upside to fair value
overvalued
PriceHK$1.61
Fair ValueHK$0.17
Quality33/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-42%
upside to fair value
overvalued
Price$477
Fair Value$279
Quality73/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Jw Cayman Therapeutics CoVertex Pharmaceuticals
Valuation
P/E (TTM)28.8×
0.34×P/S (TTM)10.06×
0.17×P/B6.59×
EV/EBITDA23.8×
PEG1.72×
Profitability
-196%Net margin36%
-73%Operating margin38%
-64%Return on equity24%
-11%Return on assets12%
Growth
148%Revenue growth (YoY)8%
23.8%Avg. growth/yr (3Y)10.6%
Avg. growth/yr (5Y)14.2%
Balance & size
0.03×Debt / equity0.03×
$96MMarket cap$123B
mixedGrowth qualityhealthy

Vertex Pharmaceuticals leads: 4 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Jw Cayman Therapeutics Coof which business quality 45 · market factors 2 Vertex Pharmaceuticalsof which business quality 77 · market factors 57
ProfitabilityMargins and returns on capital today
7
72
Quality GrowthAre margins and returns improving?
60
65
CashflowEarnings quality: real cash, not paper profit
0
79
Fin. StrengthBalance sheet, leverage, solvency risk
66
92
InvestmentDisciplined investing over empire-building
100
58
Low VolatilityCalm price path (market factor)
0
77
MomentumPrice trend over the last 3–12 months (market factor)
3
48
52W MomentumDistance to the 52-week high (market factor)
2
52
Net IssuanceBuybacks instead of dilution
77
82

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Jw Cayman Therapeutics Co

Asset-BasedHK$0.17

1 of 1 models see the stock below the current price.

Vertex Pharmaceuticals

DCF Models$429
Earnings-Based$516
Dividend Discount$7.07
Multiples$246
Asset-Based$49.27
Growth DCF$333
Economic Profit$254
Growth Earnings$672

18 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Jw Cayman Therapeutics Co
Bear HK$0.11Fair Value HK$0.17Bull HK$0.21
HK$1.61 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$477 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Jw Cayman Therapeutics Co · Health Care

Quality score33 · bottom 25%
Fair value upside-89% · bottom 25%

Vertex Pharmaceuticals · Health Care

Quality score73 · Top 25%
Fair value upside-42% · below median

Bottom line

As of Aug 5, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Jw Cayman Therapeutics Co trades at HK$1.61 versus a fair value of HK$0.17 (-89%), while Vertex Pharmaceuticals trades at $477 versus $279 (-42%).

Vertex Pharmaceuticals has the higher quality score (73/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.